Finalists ponder fate of $88M HIV facility

The four finalists for an $88 million project to build a new facility in Canada to produce an HIV vaccine say the government has left them in the dark about the reasons why no one has been selected as a winning bidder. Report

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.